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Neisseria gonorrhoeae is a sexually transmitted human mucosal pathogen. It causes a 
variety of diseases ranging fi-om uncomplicated infections of the genitalia to pelvic 
inflammatory disease and disseminated gonococcal infection. One of the mechanisms 
used by the bacteria to evade the immune system of the host is the transfer of sialic acid 
from the host substrate CMP-NANA to lipooligosaccharide molecules found on the 
surface of the bacteria. This transfer is accomplished by the action of an a-2,3-
sialyltransferase (Stase). 
The hypothesis that Stase was located in the outer membrane of N. gonorrhoeae was 
tested by enzymatic assay for the presence of Stase and by Western blot detection. Blots 
were probed with antisera generated to a multiple antigenic peptide system antigen 
containing a segment of Stase and to a maltose binding protein/Stase fusion protein. The 
subcellular fractions isolated included the inner and outer membrane, periplasm and 
cytoplasm. The inner and outer membranes were isolated by sucrose density gradient 
centrifugation, the periplasm by chloroform extraction and the cytoplasm by sonication 
and ultracentrifiigaton. Culture supernatant was also tested for the presence of Stase. 
The enzymatic assay detected the vast majority of Stase activity in the outer membrane. 
Western blot analysis confirmed that Stase was located only in the outer membrane of the 
bacteria. The presence of Stase in the outer membrane has implications for vaccine 
development. If antibodies against Stase can prevent sialylation of the bacteria, the 
immune system of the host may be able to fight off infection, decreasing the prevalence 
of gonococcal disease. 
Director: Ralph C. Judd 
ii 
TABLE OF CONTENTS 
Page 
Abstract ii 
Table of Contents iii 
List of Figures iv 
Acknowledgments v 
1. Introduction 1 
1-1. Gonococcal Morphology, Pathology, and Treatment 1 
1-2. Gonococcal Survival Strategies and Major Outer Membrane Proteins 3 
1-3. Lipooligosaccharide 6 
1-4. Sialyltransferase and Sialylation of Lipooligosaccharide 8 
1-5. Research Goal, Hypothesis, and Specific Aims 11 
2. Materials and Methods 14 
2-1. Bacterial strains, Growth, and Harvesting 14 
2-2. Isolation of Inner and Outer Membrane Fractions 14 
2-3. Isolation of Periplasm, Cytoplasm, and Culture Supernatant 15 
2-4. Protein Assay 16 
2-5. SDS-PAGE and Western Blotting 16 
2-6. Sialyltransferase Enzymatic Assay 17 
2-7. Selection of MAPS Peptide 18 
2-8. Generation of Peptide Specific Polyclonal Antiserum 18 
2-9. Enzyme-Linked Immunosorbent Assay (ELISA) 19 
2-10. Generation of Plasmid Vector pMAL-Stase 20 
2-11. Expression and Purification of MBP/Stase Fusion Protein 21 
2-12. Generation of Rabbit Polyclonal Stase Antiserum 22 
3. Results 23 
3-1. Isolation of Subcellular Fractions 23 
3-2. Enzymatic Assay for Sialyltransferase Activity 25 
3-3. Selection of Peptide Sequence for MAPS Immunogen 28 
3-4. Generation of Stase-MAPS-API Antiserum 28 
3-5. Western Blot Detection of Stase 33 
3-6. Cloning of Stase into pMAL Fusion System 33 
3-7. Expression of MBP/Stase Fusion Protein 36 
3-8. Generation of Stase/MBP Antiserum 36 
4. Discussion 41 
5. References 48 
iii 
LIST OF FIGURES 
Page 
Figure lA: Absorbance and density of strain F62 membrane fractions. 24 
Figure IB: Absorbance and density of strain F62 STOl membrane 24 
fractions. 
Figure 2: Silver stain of subcellular fractions. 26 
Figure 3: Stase enzymatic activity of subcellular fractions. 27 
Figure 4; Mac Vector analysis of Stase amino acid sequence. 29 
Figure 5: Characteristics of Stase amino acid sequence selected for 30 
MAPS peptide. 
Figure 6: Multiple antigenic peptide octomer. 31 
Figure 7: ELIS A detection of Stase-MAPS-APl antibodies. 32 
Figure 8: Coomassie stain and Western blot of subcellular fractions 34 
probed with Stase-MAPS-APl antiserum. 
Figure 9: Coomassie stain and Western blot of culture supernatant 35 
probed with Stase/MBP antiserum. 
Figure 10: pMAL-Stase vector diagram. 37 
Figure 11: Coomassie stain detection ofMBP/Stase fusion protein. 38 
Figure 12: Western blot of MBP/Stase fusion protein probed with 39 
Stase antiserum. 
Figure 13: Coomassie stain and Western blot of subcellular fractions 40 
probed with Stase/MBP antiserum. 
iv 
ACKNOWLEDGMENTS 
I thank Dr. Ralph Judd for his support and for allowing me the opportunity to 
work in his laboratory. I also thank current and former members of the Judd Lab, Dr. 
Scott Manning, Deborah Nycz, Dr. Dennis Reschke and Doug Marchion for their 
assistance with this project and for their patience in answering my questions. For their 
contributions to this project I thank Joan Strange, Dr. Rick Rest and Dawn Bell. Thanks 
also to Dr. Scott Samuels, Dr. Carol Brewer and Dr. Kevin Murray for serving on my 
committee. For their support and encouragement I thank Dr. Jean Pfau, my husband 
Matt, and my parents. Finally, I thank God because without his grace I would never have 
made it this far. 
v 
1. INTRODUCTION 
1-1. Gonococcal Morphology, Pathology, and Treatment 
Neisseria gonorrhoeae (gonococcus) is a gram-negative, kidney shaped bacterium 
that exists in pairs (Swanson, et al, 1987). It is a facultative anaerobe (Cohen and 
Sparling, 1992) that infects a variety of human mucosal surfaces including the urethra, 
endocervix, rectum, pharynx, and conjunctiva (Britigan, et al., 1985). Occasionally it is 
able to infect the blood and disseminate, causing systemic infection (Cohen and Sparling, 
1992). N. gonorrhoeae is the causative agent of gonorrhea, a sexually transmitted disease 
that is reported to affect well over a quarter of a million people every year in the United 
States (MMWR, 1997). The actual figure is greater because of incomplete reporting and 
the existence of asymptomatic infections (Britigan, et al, 1985). In most males, 
gonococcal infection causes urethritis, which results in purulent discharge and painful 
urination (Britigan, et al, 1985; Tortora, et al, 1992). Many women, however, remain 
asymptomatic and the disease may progress beyond an infection of the urethra or 
endocervix (Britigan, et al, 1985). Gonococci are not motile; they must be transported 
past the endocervix into the fallopian tubes by a carrier, probably refluxed menstrual 
blood and/or sperm (Cohen and Sparling, 1992). Transport of N. gonorrhoeae further 
into the body may lead to more serious infections. 
Serious manifestations of gonococcal infection include disseminating gonococcal 
infection (DGI), pelvic inflammatory disease (PID), salpingitis, ectopic pregnancy, 
infertility, and in infants, ophthalmia neonatorum. DGI occurs when N. gonorrhoeae 
causes bacteremia leading to skin lesions, infections of the joints - which can cause 
arthritis, and infections of the meninges and heart (Cohen and Sparling, 1992; Tortora, et 
1 
2 
al, 1992). PID is a general term referring to infections in the pelvic area and can include 
salpingitis (Tortora, et al, 1992). Salpingitis is an inflammatory infection of the 
fallopian tubes. It may result in the loss of ciliated epithelial cells and in scarring, leading 
to ectopic pregnancy and infertility (Cohen and Sparling, 1992; McGee, et al, 1992). 
PID, ectopic pregnancy and infertility are the most costly sequelae of gonococcal 
infection to treat and ectopic pregnancy can be fatal (McGee, et al, 1992). Gonococcal 
ophthalmia neonatorum, which may result in blindness, occurs when gonococci enter the 
eyes of an infant as it moves through an infected birth canal (Brooks, et al, 1995). 
Treatment of gonococcal infections is complicated by the increasing emergence of 
antibiotic-resistant strains of N. gonorrhoeae (Britigan, et ai, 1985). Gonococcal 
resistance to penicillin was first described in 1976 (Ison, 1996). Penicillinase-producing 
N. gonorrhoeae (PPNG) carrying a penicillin resistance plasmid have now spread 
worldwide. Plasmid-mediated tetracycline resistance was described in 1985 (Ison, 1996). 
Gonococcal resistance to spectinomycin and ceftriaxone has also been reported (Tortora, 
et al., 1992). Vaccination against N- gonorrhoeae, which is not yet possible, would 
decrease the use of antibiotics and slow the development of resistant strains. 
Unfortunately, vaccine and diagnostic development are hampered by the fact that humans 
are the only reservoir for the bacteria (Britigan, et al., 1985). There are no animal models 
of the disease (Cohen and Sparling, 1992). 
In vitro research provides one important level of knowledge about the bacterium. 
Other information is gleaned from research studies performed on male volunteers. 
Human trials are limited, however, because of the ethics of allowing an infection to 
proceed unchecked. Further insights into the mechanisms of pathogenesis come from 
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human fallopian tubes in organ culture (McGee, et al, 1992) and from tissue culture 
models. 
1-2. Gonococcal Survival Strategies and Major Outer Membrane Proteins 
N. gonorrhoeae use a variety of strategies to enhance survival in the host, 
including the secretion of IgA, protease (Kilian, et al, 1996), and the variation of many 
surface molecules. Pathogenic Neisseria secrete an immunoglobulin class A, subclass 1 
(IgAi) protease that may enhance gonococcal colonization of mucosal surfaces by 
cleaving the hinge region of dimeric IgAi antibodies (Cohen and Sparling, 1992). 
Secretory IgA is the main antibody isotype found in mucosal tissues and secretions 
(Kilian, et ai, 1996). It inhibits microbial colonization in a variety of ways, including 
agglutination of the bacteria, blockage of adhesins, and increase of bacterial surface 
hydrophilicity (Britigan, et al, 1985; Kilian, et ah, 1996). A decrease in the 
effectiveness of secretory IgAi molecules is likely to enhance the survival of N. 
gonorrhoeae in the host. 
Phase and antigenic variation of outer membrane molecules, including glycolipids 
and proteins, enhance the ability of gonococci to evade the immune defenses of the host. 
Phase variation is the on/off switching of surface molecule expression. Antigenic 
variation occurs when the bacteria change the epitopes displayed on their surface 
molecules. These variations may also allow the bacteria to adapt to the host 
microenvironment and respond to changes in that environment (van Putten and 
Robertson, 1995). 
Major variable gonococcal outer membrane molecules include pili (Pil), now 
known as fimbriae, opacity (Opa) proteins, porin (Por), reduction modifiable proteins 
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(Rmps) and lipooligosaccharide (LOS). Fimbriae are filaments consisting of 
homopolymers of the polypeptide pilin. They range in molecular weight from 17.5 to 26 
kDa and are extremely variable (Swanson and Koomey, 1989). Fimbriae mediate 
adherence of the bacteria to each other as well as to the mucosa of the host (Swanson, 
1990). Either no fimbriae or fimbriae of a single pilin type are expressed at any one time 
in any given cell. Pil^ gonococci are able to infect a host while Pif organisms are not 
(Swanson and Koomey, 1989). The phase and antigenic variation of fimbriae are 
controlled at the level of transcription. Variation is due to recombination of one of at 
least 12 partial, "silent", pilin coding regions, found throughout the genome, into the 
complete pilin expression gene (Cohen and Sparling, 1992; SwansOn, 1990). 
There are at least eleven related Opa proteins encoded throughout the genome of 
N. gonorrhoeae, and either no Opa proteins or up to several may be expressed in a 
particular gonococcal cell (Cohen and Sparling, 1992; Swanson, 1990). They have 
molecular weights ranging from 24 to 32 kDa (Brooks, et al, 1995), and give gonococcal 
colonies various degrees of an opaque phenotype, perhaps due to increased adherence 
between cells (Cohen and Sparhng, 1992). Like fimbriae, Opa proteins mediate 
adherence of gonococci both to each other and to host cells (Swanson, 1990). Kupsch, et 
al. (1993) demonstrated that different Opa proteins mediated different activities 
depending on which opa allele was expressed. One strain of N. gonorrhoeae studied 
showed increased adherence to and invasion of epithelial cells while other strains, 
expressing different opa alleles were shown to interact with leukocytes. Another study 
showed that in volunteers initially infected with Opa" gonococci, only Opa^ organisms 
were recovered (Cohen and Sparling, 1992). Thus it appears likely that Opa proteins play 
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a role in gonococcal infection. Opa proteins vary at a rate of 10'^/cell/generation. In the 
portions of DNA encoding the signal peptides of the opa genes there are (CTCTT)n 
repeats which vary in length, controlling the expression of Opa proteins by shifting the 
translational reading frame. (Cohen and Sparling, 1992; Swanson, 1990) Although 
relatively stable, the nucleotide sequences encoding Opa proteins can apparently be 
changed by recombination events with other Opa-encoding genes (Swanson, 1990). 
Por is the most abundant outer membrane protein. It has a molecular weight 
ranging from 32 to 39 kDa. Por proteins associate noncovalently in groups of three 
(Elkins and Sparling, 1990). Por functions as a pore through the outer membrane of N. 
gonorrhoeae allowing for the transport of hydrophilic molecules (Britigan, et al, 1985). 
There are two subclasses of Por, PorA and PorB. PorA is associated with stable serum 
resistance. Gonococci expressing this type of serum resistance are associated with 
disseminating infections (Cohen and Sparling, 1992; Elkins and Sparling, 1990; Judd and 
Shafer, 1989). Unlike pilin and Opa proteins, Por type does not vary within a strain of N. 
gonorrhoeae, and only one antigenic type of Por is produced by a particular strain (Judd 
and Shafer, 1989). The immunogenic, surface-exposed regions of the molecule probably 
vary as a result of immunological pressure from the host (Elkins and Sparling, 1990). 
Reduction modifiable protein has a molecular weight of about 33 kDa, which 
increases when the protein is reduced (Brooks, et al, 1995; Judd, 1982). It is an 
antigenically conserved protein constitutively expressed in gonococcal strains and is 
closely associated with Por (Wetzler, et al, 1989; Judd, 1982). Rmps api^ar to assist the 
bacterium in evading the immune system of the host by inducing blocking antibodies that 
interfere with the action of anti-Por and anti-LOS antibodies. Blocking antibodies may 
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increase the susceptibility of a host to gonococcal reinfection (Cohen and Sparling, 
1992). 
1-3. Lipooligosaccharide 
Lipooligosaccharide (LOS), a molecule with a molecular weight of 3 to 7 kDa, is 
found on the surface of N. gonorrhoeae (Schneider, et al, 1984). It is composed of three 
regions: lipid A, the inner core, and the outer core (Brooks, et al, 1995). Lipid A 
anchors LOS in the outer membrane (van Putten and Robertson, 1995). Variable, non­
repeating outer core oligosaccharide units are attached to the lipid A by an inner core of 
hydrophilic sugar molecules (Brooks, et al, 1995). LOS lacks the repeating O antigens 
found in the lipopolysaccharide molecules of enteric gram-negative bacteria (Mandrell, et 
al., 1986, Schneider, et al, 1984). 
LOS is responsible for many of the pathogenic effects of N. gonorrhoeae. For 
example, McGee, et al (1992) demonstrated that tumor necrosis factor a (TNF- a) was 
induced by gonococcal LOS in the fallopian tube organ culture model. TNF- a was 
shown to elicit sloughing of ciliated epithelial cells in a dose dependent manner. When 
dexamethasone, a chemical that blocked production of TNF, was added, it prevented 
damage to the mucosa in spite of the presence of the LOS. This suggested that the 
production of gonococcal products like LOS may damage host cells indirectly by 
inducing the expression of TNF- a and possibly other cytokines. Destruction of ciliated 
cells by induced cytokines may inhibit the movement of a fertilized ovum from the 
fallopian tube to the uterus leading to ectopic pregnancy. 
The outer core oligosaccharides of gonococcal LOS play a different role in 
gonococcal pathogenesis. Mutants deficient in the synthesis of outer core 
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oligosaccharides exhibited increased sensitivity to complement-mediated serum killing 
by the alternative complement pathway, i.e. in the absence of antibodies (van Putten and 
Robertson, 1995). Longer LOS may serve to hide lytic epitopes on other surface 
components (van Putten and Robertson, 1995), as well as to inhibit the activation of 
zymogen CI of the classical complement cascade (Schweinle, et al, 1989). In addition, 
gonococcal LOS mimics human paraglobosides, precursors of the ABH antigens on 
human erythrocytes. This may serve to decrease its immunogenicity (Mandrell and 
Apicella, 1993). The variability of LOS also makes it useful to the bacteria as a method 
of evading the humoral immune system of the host (van Putten and Robertson, 1995; 
Schneider, et ai, 1985). 
LOS is highly variable (van Putten, 1993). A single cell can display antigenically 
different LOS molecules simultaneously (Apicella, et al. 1987) and a single strain may 
produce up to six structurally different LOS molecules (Schneider, et al., 1988). The 
most abundant molecule(s) determine the LOS phenotype and vary spontaneously at a 
rate of 10"^ to 10"^ (van Putten and Robertson, 1995). The phenotype of LOS may be 
influenced by the conditions in which the bacterium grows (Schneider, et al, 1988). The 
regulation of LOS expression is not yet fully understood. It is probable that genes 
involved in the synthesis of various outer core sugar units can be placed in frame or out 
of frame by frameshift mutations. For example, three of the genes responsible for the 
synthesis of a Gaipi-4GluNAc moiety contain poly-G tracts that may prevent the 
expression of the genes by addition or deletion of a single nucleotide. The resulting 
frameshift mutation would disrupt the open reading frame and change the LOS phenotype 
(van Putten and Robertson, 1995). 
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1-4. Sialyltransferase and Sialylation of Lipooligosaccharide 
Further variation of LOS occurs through the action of an a-2,3-sialyltransferase 
(Stase) (Gilbert, et al., 1996) found in all pathogenic strains of N. gonorrhoeae and 
Neisseria meningitidis (Mandrell, et al, 1993). Stase is a 43 kDa enzyme (Gilbert, et al, 
1996) that catalyzes the transfer of sialic acid, in a dose-dependent manner (Frangipane 
and Rest, 1993), from the substrate, cytidine 5'-monophospho-N-acetylneuraminic acid 
(CMP-NANA) to the Galj31-4GluNAc moiety found on some LOS molecules (Apicella, 
et al, 1990; Gilbert, et al, 1996; van Putten, 1993). Apicella, et al (1990) demonstrated 
by immunoelectron microscopy that this transfer occurred in vivo. Since CMP-NANA 
was not produced by N. gonorrhoeae (Apicella, et al, 1990; Frosch, et al, 1989), sialic 
acid was provided by the CMP-NANA found in host serum, secretions and cells (van 
Putten and Robertson, 1995, Smith, et al, 1995). In an experiment by Parsons, et al. 
(1989) there was no observable de novo protein expression induced by the presence of 
CMP-NANA, indicating that Stase was constitutively expressed. The interconversion 
between sialylatable LOS (LOS that contains the Gal(31-4GluNAc moiety) and non-
sialylatable forms of LOS allows N. gonorrhoeae to adapt to different host environments 
as infection proceeds. 
Sialylation appears to play a role in the progression of gonococcal infection. 
Schneider, et a/. (1991) showed that, of 36 naturally infected males examined, gonococci 
recovered from all 36 patients expressed sialylatable LOS. It was further demonstrated 
that gonococci can change LOS phenotype in vivo. Two volunteers were inoculated with 
gonococci expressing non-sialylatable (3.6 kDa) LOS. Gonococci isolated from the urine 
sediments of the subjects were examined at different stages of the infection. The 
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gonococci displayed the initial LOS type until the onset of inflammation and dysuria 
when sialylatable LOS began to be expressed. No gonococci expressing the original 
unsialylatable 3.6 kDa LOS were recovered after the onset of urethritis and urethral 
discharge. 
There is evidence that the sialylation of LOS influences the passage of N. 
gonorrhoeae across the "mucosal barrier" and the resistance of the bacteria to serum 
killing. Sialylated gonococci were inhibited from entering epithelial cells, and the 
invasiveness of the bacteria appeared to be dependent on the number of sialic acid 
residues displayed on the bacterial surface (van Putten, 1993). Once the bacteria 
overcome mucosal defenses and enter the host, sialylation becomes beneficial. Many 
strains of N. gonorrhoeae from fresh isolates exhibited a serum resistance that was lost 
upon subculture (Ward, et al, 1970). This serum resistance was shown to be a result of 
the sialylation of LOS (Parsons, et ai, 1989). 
The bactericidal effect of normal human sera on serum-sensitive N. gonorrhoeae 
was mainly due to the presence of IgM directed against lytic epitopes on LOS (Apicella, 
et al, 1986; Rice, et al, 1980). It was shown that when LOS was sialylated, these sites 
were blocked (Parsons, et al, 1989; Smith, et al, 1992). When gonococcal strains wild 
type F62 and JBl, a mutant deficient in Stase activity (Bramely, et al, 1995), were 
incubated with normal human sera in the presence of CMP-NANA, it was observed that 
binding of complement component C3 was significantly reduced in the parent strain but 
not in the mutant strain (Gill, et al, 1996). This indicated that the presence of sialylated 
LOS decreased the amount of complement that bound to the bacteria. Inhibition of the 
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classical complement pathway, which mediates serum killing, contributed to serum 
resistance (Frangipane and Rest, 1993). 
Sialylated LOS also protected N. gonorrhoeae from complement-mediated killing 
by anti-PorA and anti-PorB sera as well as from killing by antisera raised against the 
whole gonococcal cell. The protection appeared to be due to an inhibition of the 
alternative complement cascade rather than interference with the binding of anti-Por 
antibodies (Wetzler, et al, 1992). This is significant because in vitro experiments 
showed that the effectiveness of membrane attack complexes was increased 40% by the 
presence of the alternative complement pathway compared to the classical pathway alone 
(Rice, 1989). 
Sialylation also enhanced gonococcal survival by a delay in complement-
mediated opsonophagocytosis (Kim, et al, 1992) and by an increase in gonococcal 
resistance to phagocytic killing by polymorphonuclear phagocytes (PMNs) (Gill, et al, 
1996). In the presence of anti-Por antibodies, phagocytic cells were unable to kill 
sialylated gonococci by opsonophagocytosis (Wetzler, et al, 1992). The decrease in 
phagocytic killing by PMNs may be due to decreased binding and cleavage of C3 (Gill, et 
al, 1996) and/or by impaired attachment of gonococci to PMNs (van Putten, 1993). 
Several pieces of evidence indicated, either directly or by process of elimination, 
that the gonococcal sialyltransferase was located in the outer membrane. First, Stase 
appears to have a signal peptide (Gilbert, et al., 1996) indicating that it is not a 
cytoplasmic protein. Second, since gonococci do not produce the CMP-NANA substrate 
(Frosch, et al, 1989), CMP-NANA would have to be imported if Stase was located in the 
periplasm, inner membrane or cytoplasm. Unsialylated LOS already on the surface of the 
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bacterium could be sialylated (Mandrell, et al, 1993), thus the LOS to be sialylated 
would have to be impori;ed from the surface. Then, after sialylation, it would have to be 
exported to the surface to be displayed. These import and export processes would 
probably require special transport proteins. Third, Stase activity can be extracted with 
Triton X-100, a mild detergent, implying that it is located near the surface of the 
gonococci (Mandrell and Apicella, 1993). Fourth, it is unlikely that the enzyme is 
secreted into the surroundings because this would decrease the efficiency of the 
interaction between the enzyme and substrates with regard to timing and orientation. It 
would also be costly to the bacteria in terms of protein production, and as mentioned 
above, no de novo protein synthesis was seen in the presence of the substrate CMP-
NANA (Parsons, et ai, 1989). 
If it is shown to be in the outer membrane. Stase may be a vaccine candidate, 
especially if its immunogenic epitopes are conserved among different strains. If 
antibodies directed against Stase prevented LOS sialylation, then although adherence and 
cell invasion may occur (Gill, et al., 1996), host immune defenses would be better able to 
fight off the infection and possibly prevent the dissemination of the bacteria. 
1-5. Research Goal, Hypothesis, and Specific Aims 
The goal of this projœt was to determine which subcellular fraction of the 
gonococcal cell contained Stase. Rabbit anti-Stase antibodies were made against a 
Multiple Antigenic Peptide System (MAPS) peptide containing a portion of the Stase 
amino acid sequence predicted to be antigenic and surface exposed. These antibodies 
were then used on a Western blot to probe the cytoplasm, inner membrane, periplasm, 
outer membrane, and culture supernatant fractions to determine the subcellular location 
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of Stase. As a confirmation, a maltose binding protein (MBP)/Stase fusion protein was 
generated and used to immunize a rabbit. The rabbit Stase/MBP antiserum generated was 
also used for Western blot analysis. A gonococcal Stase deficient mutant, strain F62 
STOl, with a kanamycin resistance cassette used for an insertional deletion of the gene 
encoding Stase, served as a negative control (unpublished). 
Hypothesis; Sialyltransferase is located in the outer membrane of Neisseria 
gonorrhoeae. 
The following Specific Aims were investigated to test the hypothesis; 
1. The culture supernatant and subcellular fractions, i.e. outer membrane, periplasm, 
inner membrane and cytoplasm, of N. gonorrhoeae strains wild type F62 and Stase 
deletion mutant F62 STOl were isolated. 
2. In collaboration with Dr. Rick Rest (Allegheny University of the Health Sciences 
(AUHS), Philadelphia, PA), the subcellular fi^actions and supernatant of F62 and F62 
STOl were assayed for Stase activity. 
3 A peptide sequence from Stase was selected, based on hydrophilicity, surface 
exposure and antigenicity as predicted by computer model, and used to make a MAPS 
immunogen. 
4. Rabbit Stase antiserum was generated by immunization with the MAPS immunogen. 
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5. Western blots of the isolated fractions were probed with Stase-MAPS antiserum to 
identify the fraction containing Stase. 
6. The gonococcal gene encoding Stase was cloned into the pMAL-c2 vector system and 
used to transform Escherichia coli cells. Transformed cells expressed a MBP/Stase 
fusion protein that was purified by batch incubation on amylose resin. 
7. Rabbit Stase/MBP antiserum was generated by immunization of a rabbit with the 
fusion protein and used to confirm results obtained in step 5 above. 
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2. MATERIALS AND METHODS 
2-1. Bacterial strains. Growth, and Harvesting 
Neisseria gonorrhoeae strains F62 and F62 STOl, gifts ft^om Dr. Rick Rest 
(AUHS), were selected for transparency (Opa") and lack of pili, and grown for 16 hours 
in 5% CO2 at 37°C on clear typing media (Swanson, 1978). Cells were harvested by 
swabbing into 3ml of GC broth to an ODeoonm^l- One milliliter of culture was then 
inoculated into 50ml of GC broth and grown, with shaking, at 37°C until it had reached 
mid-log phase as determined by optical density (about 4 hours). Two and one half 
milliliters of mid-log phase culture were inoculated into 250ml of GC broth and 
incubated as described above. Once the cells in the 250ml culture were in mid-log phase, 
they were harvested by centrifugation at 12,000xg for 10 minutes. 
2-2. Isolation of Inner and Outer Membrane Fractions 
A modification of the procedure of Osbom and Munson (1974) was used. 
Briefly, the pellet generated above (representing 250ml of original culture) was 
resuspended in 6.25ml of cold 200mM Tris-HCl, pH 8.0 (measured at room temperature) 
and diluted with an equal volume of cold IM sucrose, 200mM Tris-HCl, pH 8.0 
(measured at room temperature). Two resuspended pellets were combined and fi"ozen at 
-70°C. The suspension was thawed on ice and the following pre-chilled reagents were 
added sequentially, with vortex mixing after the addition of each reagent; 25}xl of250mM 
EDTA, lOOjLil of N-acetylmuramidase (13,000 units/ml in triple distilled water [3xdH20]) 
(Sigma, St. Louis, MO; mutanolysin M9901) and 12.5ml of ice cold 3xdH20. The 
3xdH20 was added forcefully by pipet. The cells were gently rocked overnight at 4°C, 
then sonicated on ice by four, 20 second bursts at 50% power (setting 3) using the 
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microtip on a Fisher 550 Sonic Dismembranator (Fisher Scientific, Santa Clara, CA). 
The preparation was then centrifuged at 12,000xg for 10 min. at 4°C. The supernatant 
was decanted and centrifuged for 30 min. more at 12,000xg. Supernatant was removed 
and ultracentrifuged at 4°C for 2 hours at 225,000xg in a Ti80 rotor (Beckman, Fullerton, 
CA). The resulting membrane pellets were resuspended in 1ml of 18% (w/w) sucrose 
containing ImM EDTA and 0.2mM dithiothreitol (DTT). An isopycnic sucrose gradient 
was prepared in a 37ml polypropylene tube by layering the following sucrose (w/w) 
solutions containing ImM EDTA and 0.2mM DTT; 6ml of 60% sucrose solution 
followed by 5ml each of 55%, 50%, 45%, 35%, 25% and 20% sucrose. One milliliter of 
the membrane suspension was then layered on top and the gradient was centrifuged at 
80,000xg for 48 hours at 4°C in an SW28 rotor (Beckman). Using a peristaltic pump, 
fractions were collected off the top of the gradient in 1ml aliquots. Fractions were 
analyzed by refractometry and absorbance at 280nm. Fractions corresponding to the 
central portion of the outer membrane peak were combined as were the fractions 
corresponding to the main portion of the inner membrane peak. 
2-3. Isolation of Periplasm, Cytoplasm, and Culture Supernatant 
Periplasm was isolated using a modification of the procedure described by Judd 
and Porcella (1993). Briefly, cells were grown on plates as described above and 
harvested to OD^oonm^ 0.68 in ice cold Dulbecco's phosphate-buffered saline, pH 7.4 
(DPBS) containing magnesium and calcium ions. The cells were washed three times in 
cold DPBS. The final wash was removed and the cells were resuspended, with vortexing, 
in 20fil of chloroform (Baker, Phillipsburg, NJ)/1.5ml of original suspension. After a 15 
min. incubation at 22°C (standard) or 4°C (to preserve enzymatic activity), lOOjxl of ice 
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cold 0.0 IM Tris-HCl, pH 8.0 (measured at room temperature) was added with vortexing, 
and cells were pelleted by centrifugation at full speed for 5 min. in a microfuge. The 
supernatant contained the periplasmic contents. 
Cytoplasm was isolated by growing, harvesting and washing cells as described in 
the periplasm extraction procedure above. After the final wash, cells were resuspended 
in 100111 DPBS/1.5ml original suspension, and sonicated with four, 20 sec. bursts at 50% 
power (setting 3) on a Fisher 550 Sonic Dismembranator using a microtip. The 
suspension was then centrifuged 10 min. at full speed in a microfuge. The supernatant 
was removed and ultracentrifuged at 130,000xg for one hour. The clarified supernatant 
contained the cytoplasmic contents. 
Supernatant was isolated from cells grown and harvested as described above. The 
supernatant was removed &om the cell pellet and ultracentrifuged at 225,000xg for 4 
hours at 4°C with a Ti80 rotor (Beckman). The resulting supernatant was the culture 
supernatant used in the following experiments. 
2-4. Protein Assay 
To determine the protein concentrations of the subcellular fractions and 
supernatant, a BCA Protein Assay Reagent Kit (Pierce, Rockford, IL; kit # 23225) was 
used. Protein concentration was determined as described in the microtiter plate protocol 
with the absorbance readings made at 570nm (within the acceptable range of 540-590nm) 
and the incubation was performed as described for the enhanced protocol (60°C for 30 
min.). BSA standards were used to generate a standard curve. 
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2-5. SDS-PAGE and Western Blotting 
Contents of the subcellular fractions were separated by sodium dodecyl sulfate 
polyacrylamide gel electrophoresis (SDS-PAGE) performed using a modification of the 
tris-glycine discontinuous system of Laemmli (1970) as described by Judd (1987). 
Western blotting was performed essentially as previously described (Batteiger, et al., 
1982; Judd, 1988). Briefly, proteins were transferred to a Millipor (Bedford, MA) 
Immobilon polyvinylidene difluoride (PVDF) membranes by immunoblotting in 20 mM 
sodium phosphate buffer, pH 8.0 for approximately 4 hours at 0.6 Amps, using a Bio-Rad 
(Richmond, CA) Trans-Blot Cell. The blots were blocked with 0.05% Tween-20 in 
DPBS and probed with either rabbit anti-Stase-MAPS-APl (1:50 dilution in DPBS), 
rabbit anti-Stase/MBP (preabsorbed 1 ;2 with E. coli DH5a cell lysate, at a I; 134 dilution 
in DPBS), or anti-Stase sera, a gift from Dr. Rick Rest (AUHS) generated against a 
purified Stase recombinant protein. Other antisera were generated as described below. 
Secondary antibody. Protein A-horseradish peroxidase (Boehringer Mannheim, 
Indianapolis, IN) was added in a 1:2500 dilution. A buffered 4-chloro-1 -naphthol, 
hydrogen peroxide solution was used to develop the blots. 
2-6. Siaiyltransferase Enzymatic Assay 
An enzymatic assay for the presence of siaiyltransferase was performed on the 
subcellular fractions, isolated as described above, by Dr. Rick Rest's laboratory (AUHS). 
Incorporation of the ''^C labeled N-Acetyl Neuraminic Acid (NANA) portion of CMP-
NANA into purified LOS molecules was used to detect Stase activity essentially as 
described by Mandrell, et al. (1993). The assay mixtures contained sodium phosphate 
(0.5M, pH 6.8), 2% bovine serum albumin, purified LOS fi-om N. gonorrhoeae F62 (lp,l. 
18 
lOmg/ml), CMP-NANA (Sigma, 0.86ng) and CMP-[sialic-4,5,6,7,8,9-'^C]NANA 
(Dupont-NEN, Boston, MA; 0.03}xCi/ml, 1.5ul). Each assay had a final volume of 50|ul 
with 0.5% Triton X-100 as the diluent. Two or 4|i,l aliquots of one of the subcellular 
fractions prepared as described above were added to each assay mixture to start the 
reaction. Reaction mixtures were incubated at 37°C for 15 min. The reaction was then 
stopped by addition of 0.5ml of a 5% phosphotungstic acid-15% trichloroacetic acid 
solution (PTA-TCA), which precipitates BSA-LOS complexes. After centrifugation, the 
precipitate was washed twice with PTA-TCA, solubilized in 0.5ml of Solvable (Packard, 
Meriden, CT), scintillation fluid was added and the sample was counted in a liquid 
scintillation counter. Background counts of approximately 150 cpm were subtracted 
from the experimental value of each sample. Stase specific activity was expressed as 
cpm/|Lig of protein in sample. 
2-7. Selection of MAPS Peptide 
The MAPS molecule used to generate rabbit polyclonal antiserum consisted of 
eight identical peptides ("^ENRNEKYDYYF^^) attached to a polylysine backbone at 
by alanine residues. The peptide sequence was selected from hydrophilicity, antigenicity, 
flexibility and surface probability plots of the amino acid sequence of sialyltransferase 
generated by MacVector software (Kyte-Doolittle algorithm). Stase-MAPS-antigenic 
peptide 1 (Stase-MAPS-APl) was synthesized by the University of Montana Molecular 
Biology Facility (UMMBF-Missoula, MT). 
2-8. Generation of Peptide-Specific Polyclonal Antiserum 
A New Zealand White rabbit was used to generate polyclonal antisera against 
Stase-MAPS-APl. Primary immunization was Img/ml Stase-MAPS-APl in 500]liI of 
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SxdHiO and 500(xl complete Freund's adjuvant (CFA) injected subcutaneously in four 
sites. Secondary immunization was the same as the primary except incomplete Freund's 
adjuvant (IFA) replaced complete Freund's adjuvant. Boosters were given every two to 
three weeks and ranged from 0.2mg to Img of Stase-MAPS-APl. The first booster was 
intramuscular in IF A and subsequent boosters were intravenous in 3xdH20. 
2-9. Enzyme-Linked Immunosorbent Assay (ELISA) 
ELISA was performed in 96 well Immulon II plates (Dynatech Laboratories, 
Chantilly, VA) coated with the Stase-MAPS-APl (lO^g/ml in SxdHiO and/or DPBS) for 
18 hours at 4°C, (lOOjul/well). Wells were then blocked with DPBS, 0.05% Tween-20 for 
18 hours at 4"C to prevent binding of non-specific antibodies. Antiserum was added at a 
starting dilution of 1:100 in blocking buffer (lOOjil/well) and two-fold serial dilutions 
were made to a final dilution of 1:12,800. Negative controls consisted of normal rabbit 
sera as the primary antisera and wells coated with an irrelevant MAPS antigen containing 
a peptide from the gonococcal multiple transferable resistance protein C (MtrC). Afl;er an 
18 hour incubation at 4°C, wells were washed 5x with 0.05% Tween-20 in DPBS 
(lOOfxl/well/wash) and incubated with goat anti-rabbit IgG whole molecule, alkaline 
phosphatase conjugate (1:1000 in blocking buffer, lOOitil/well) for two hours at 37°C. 
Wells were washed 5x with 0.05% Tween-20 in DPBS (100|al/well/wash). To detect the 
presence of anti-Stase-MAPS-APl antibodies, 150fxl/well of p-nitro phenyl phosphate 
(PNPP) in diethanolamine buffer, pH 9.8 (one tablet/15ml at room temperature) were 
added and incubated at room temperature for 30 min. Absorbance was read by V^ax 
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ELISA plate reader (Molecular Devices, Sunnyvale, CA) running the Softmax program at 
a wavelength of 405nm. ELISA was used to determine antibody titer. 
2-10. Generation of Plasmid Vector pMAL-Stase 
The pMAL-c2 vector (New England BioLabs (NEB), Beverly, MA; kit #800-645) 
was engineered to contain a Stase-encoding insert and was used to generate a Stase/MBP 
fiision protein. The vector contained an ampicillin resistance marker, the inducible Ptac 
promoter, the gene for MBP (malE), followed by a polylinker containing restriction 
endonuclease cleavage sites and lacZa. It also contained the gene lad, encoding the Lac 
repressor that prevented transcription from Ptac until IPTG was added. Interference with 
plasmid function by transcription from Ptac was prevented by an rrnB terminator 
sequence. A unique set of oligonucleotide primers containing engineered endonuclease 
cleavage sites and complementary to the ends of the Stase gene (GenBank accession # 
NGU60664) were synthesized by the UMMBF. The forward primer 
(Stase 5'): 5'-GGATTCATGGGGTTGAAAAAAGTCTGTTTGACC 
{EcdK I site in bold) and the reverse primer (Stase 3'); 
5'GCTCTAGATTAATTTTTATCGTCAAATGTCAAAAT {Xba I site in bold) were 
used to amplify the gonococcal Stase gene from strain F62 by PGR (Boehringer 
Mannheim Expand High Fidelity PGR System), using genomic DNA as the template. 
The product was purified using the QIAquick method for DNA purification from PGR 
reactions (QIAGEN, Los Angeles, CA) and double-digested with Xba I and EcdR. I 
restriction endonucleases (NEB). The pMAL-c2 vector (NEB) was double-digested with 
Xba I and EcdR. I, calf intestine alkaline phosphatase (CIP) (NEB) treated and purified by 
the QIAquick method. The ligation reaction was performed using the Ready-To-Go T4 
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DNA Ligase kit (Pharmacia Biotech, Piscataway, NJ; kit #27-0361-01) and the resulting 
msert-containing plasmids (pMAL-Stase) were transformed into Library Efficiency 
DHSaMCR Competent Cells (Life Technologies, Grand Island, NY). Transformed cells 
were plated onto LB-Ampnoug/mi, X-gaUoug/mi, IPTGo.inM media. IPTG induced 
transcription from the Ptac promoter allowing the expression of the MBP/Stase fusion 
protein. The termination codon on the end of the fusion protein prevents the expression 
of P-galactosidase a resulting in white colonies on X-gal plates. QIAGEN plasmid 
preparations were made from selected white colonies, double digests (Xba I and EcoK I) 
were performed and the products run on a 1% agarose DNA gel stained with ethidium 
bromide to confirm the presence of the pMAL-Stase plasmid. 1 Kb DNA Ladder 
(GibcoBRL, Grand Island, NY) was used as the size standard. Plasmid DNA was 
sequenced using the pMAL primer (UMMBF) to confirm the correct insertion of the 
clone. 
2-11. Expression and Purifîcation of MBP/Stase Fusion Protein 
A modification of the NEB protocol for Protein Fusion and Purification System 
#800 was used to express and purify the Maltose Binding Protein (MBP)/Stase fusion 
protein. Briefly, a 10ml overnight culture (grown in LB-Ampnoug/mi) of cells containing 
pMAL-Stase was diluted 1 ; 10 in LB-Ampnoug/mi and grown to an ODeoo of approximately 
0.5. The culture was then induced with IPTG, at a final concentration of ImM, for 3 
hours. Cells were centrifuged at 4,000xg for 20 min., resuspended in 40ml of lysis buffer 
(described in the NEB protocol), and frozen overnight at -20°C. Cells were thawed in ice 
water and sonicated with ten 15 second bursts at 50% power (setting 3) on a Fisher 550 
Sonic Dismembranator using a microtip. NaCl was added to a final concentration of 
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0.5M and the mixture was centrifuged for 30 min. at 9,000xg. Supernatant was removed, 
placed on amylose resin (5ml bed volume/tube) (NEB) and rocked overnight. Batches of 
resin were centrifuged at 3000 rpm in a Beckman Model TJ-6 swinging bucket centrifuge 
and washed with three bed volumes of column buffer+0.25% Tween-20 (described in the 
NEB protocol) followed by a wash with five bed volumes of column buffer. Each wash 
was followed by a low speed (3000 rpm) spin in a Beckman TJ-6 centrifuge. Ten 
milliliters of column buffer+lOmM maltose was added to each batch. Tubes were spun 
down as described for the washes and the column buffer containing the MBP/Stase fusion 
protein was aspirated off, dialyzed against distilled water and lyophilized. 
2-12. Generation of Rabbit Polyclonal Stase Antiserum 
The purified fusion protein obtained above was solubilized in DPBS (0.5 mg/ml 
as determined by BCA protein assay) and used to immunize a New Zealand White rabbit. 
The primary immunization was 0.26mg of MBP/Stase fusion protein in CFA given 
subcutaneously in four sites. The secondary immunization was 0.38mg of fusion protein 
in IFA given subcutaneously in four sites. IV boosts were given two weeks apart and 
consisted of lOOmg of fusion protein and 140mg of fusion protein respectively. 
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3. RESULTS 
3-1. Isolation of Subcellular Fractions 
Outer membrane, periplasmic, inner membrane and cytoplasmic fractions were 
isolated from both N. gonorrhoeae strain F62 (parent) and N. gonorrhoeae F62 STOl 
(Stase deletent). The outer membrane of each strain was separated from the inner 
membrane by isopycnic sucrose density gradient centrifugation. The gradients were 
fractionated into 1ml fractions and the absorbance at 280nm (the wavelength 
corresponding to the absorbance peak of proteins) of each fraction was measured. When 
the Also of every other fraction was plotted sequentially from the top of the gradient to 
the bottom, two protein absorbance peaks were observed (Figures lA and IB). In the 
gradient separation of strain F62, the first peak was found in fractions 1-11 and the main 
portion of the second peak corresponded to fractions 12-23. In the STOl fractions, the 
first peak was found in fractions 1-13 and the second in fractions 14-26. The density of 
every other fraction (beginning with fraction 1 in each gradient) was measured by 
refractometry. For strain F62, the density ranges of the first and second peaks (averaged 
over two gradients) were 1.09g/cm^ to 1.15g/cm^, and 1.17g/cm^ to 1.25g/cm^, 
respectively. The peaks of strain STOl had a density range of 1.08 g/cm^ to 1.15g/cm^ 
for the first peak and 1.17g/cm^ to 1.25g/cm^ for the second peak. The densities of the 
iimer and outer membranes of other Gram negative bacteria are approximately l.lg/cm^ 
and 1.22g/cm^ respectively (Judd, et al, 1996). These values fell within the density 
ranges corresponding to two protein peaks identified by absorbance, which led to the 
conclusion that the first peak contained irmer membrane proteins and the second peak 
contained outer membrane proteins. 
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Figure 1. Absorbancezso and density (g/ml) of fractions showing sucrose gradient 
membrane separations of (A) TV. gonorrhoeae F62 and (B) N. gonorrhoeae F62 STOl 
by isopycnic centrifugation. The first peak corresponded to the inner membrane and the 
second peak corresponded to the outer membrane. 
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This was confirmed by cytochrome, sugar dehydrogenase and immunological assays (Dr. 
Ralph Judd, personal communication). Fractions from the middle of each peak were 
combined and used for enzymatic assays and Western blotting detection. 
Components in the different subcellular fractions were compared via a 17.5% 
silver-stained SDS-PAGE gel (Figure 2). Outer membrane markers such as For and LOS 
were seen in the outer membrane fractions. This was confirmed by antibody binding 
previously described by Judd, et al. (1996). Lanes containing periplasm displayed a band 
assumed to be the 44 kDa protein found to be the dominant protein in the periplasm (Judd 
and Forcella, 1993). The supernatant showed a high protein (peptide) content by BCA 
protein assay, but very little if any was attributable to gonococci as the control 
supernatant (sterile) contained more protein (peptides) than supernatant taken from 
bacterial cultures (data not shown). 
3-2. Enzymatic Assay for Sialyltransferase Activity 
Coded samples of the subcellular fractions oiN. gonorrhoeae strains F62 and 
STOl were assayed for Stase activity by Dr. Rick Rest's Laboratory (AUHS) (see 
Materials and Methods). The vast majority of Stase activity was found in the outer 
membrane fraction of strain F62. The only fractions with activity wgre the F62 outer 
membrane with a specific activity (cpm/jag protein) of 9050 ± 326 and the F62 inner 
membrane with a specific activity of 267 ± 6.0cpm/|ag protein (Figure 3). As expected, 
the STOl fractions (negative controls) showed no Stase activity, and no Stase activity 
was detected in the supernatant fractions. 
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Subcellular Fractions of N. gonorrhoeae Wild Type Strain F62 and 
Stase-Defîcient Mutant Strain F62 STOl as Detected by Silver 
Stain 
silver stain 
Figure 2. Comparison of the different protein banding patterns of the subcellular 
fractions of N. gonorrhoeae strains F62 and F62 STOl by silver stain. Proteins were 
separated on a 17.5% SDS-PAGE gel. Outer membrane markers Por and LOS are 
indicated. WC- whole cell lysate, OM- outer membrane, Peri - periplasm, IM- inner 
membrane, Cyto.- cytoplasm, MW- molecular weight markers, expressed in kilodaltons 
(kDa). 
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Figure 3. Subcellular fractions and culture supematants of iV. gonorrhoeae strains F62 
and STOl were assayed for Stase activity. Only the outer membrane of strain F62 
showed significant activity with 9050 ± 326cpm,''ng of protein. The inner membrane 
fraction of strain F62 had a minor amount of Stase based on its activity of 267 ± 6.0 
cpm/fig of protein. None of the STOl fractions (negative controls) showed any Stase 
activity. OM- outer membrane. Peri.- periplasm, IM- inner membrane, €>40.- cytoplasm. 
Sup.- supernatant. 
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3-3. Selection of Peptide Sequence for MAPS Immunogen 
The nucleotide sequence for Stase (GenBank accession number NGU60664) was 
converted to the amino acid sequence by the DNA Strider computer software and 
analyzed by the Mac Vector software for hydrophilicity, surface probability, flexibility 
and antigenic index (Figure 4). The sequence ^^ENRNEKYDYYF^^ (Figure 5) was 
selected because it had the highest probability of being hydrophilic, surface-exposed and 
antigenic. An octomeric multiple antigenic peptide (Stase-MAPS-APl) was synthesized 
with this sequence linked to a polylysine backbone by alanine residues (Figure 6). 
3-4. Generation Stase-MAPS-APl Antiserum 
A New Zealand White rabbit was immunized with Stase-MAPS-APl and a 
detectable response was observed by ELIS A (Figure 7). Antibody titer was determined 
by identifying the dilution of Stase-MAPS antiserum that had an absorbance value equal 
to twice the absorbance value of the 1.100 dilution of NRS. The titer of antibody was 
found to be between 1600 and 3200. There was no significant above background 
recognition of an irrelevant MAPS antigen containing a peptide from the gonococcal 
multiple transferable resistance protein C (MtrC), indicating that the lysine backbone did 
not act as an epitope for antibody generation. Typically, antibodies are not generated to 
the lysine core of MAPS antigens (Yen, 1995). Normal rabbit serum (NRS) was used as 
a negative control and did not display an above background reaction to MtrC-MAPS 
coated wells. 
29 
Hydrophilidty Window Size = 7 Scale = Kyte-Pgoljttfe 
00-1 ! = 






00- f ^ 00 — i 1 • 1 1 
50 100 150 200 250 300 350 
_ 1.00 










Figure 4. Mac Vector computer algorithm analysis of the Stase ammo acid sequence. 
Numbers along the horizontal axis indicate the amino acid number beginning with the N-
terminus. Arrowheads indicate the sequence selected for Stase-MAPS-APl (amino acids 
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Figure 5. Predicted characteristics of the sequence selected for generation of MAPS 
peptide. The sequence ^^ENRNEKYDYYF^" (underscored with dotted line) was selected 
based on computer algorithm predicted (MacVector software) hydrophilicity, surface 
probability, flexibility and antigenic index. 
31 
Multiple Antigenic Peptide 
ENRNEKYDYYFA . / AFYYDYKENRNE 
Lvs 
ENRNEKYDYYFA ^ . / VFYYDYKENRNE 
Lvs-Lvs 
ENRNEKYDYYFA / \ AFYYDYKENRNE 
\Lys Lys/ 
ENRNEKYDYYFA ^ \\FYYDYKENRNE 
Figure 6. Stase-MAPS-APl is an octomeric peptide antigen containing eight copies of 
the selected Stase peptide sequence ^^ENRNEKYDYYF^ linked to a lysine backbone. 
The alanine residue directly linked to the lysine backbone was used as a spacer and was 
not part of the selected amino acid sequence. 
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ELISA Detection of Stase-MAPS-
APl Antibodies 
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Figure 7. Detection of Stase-MAPS-APl antibodies was accomplished by ELISA (see 
Materials and Methods). Wells were coated with Stase-MAPS-APl and incubated with 
two-fold serial dilutions (100-6400) of Stase-MAPS-APl antiserum (Anti-MAPS, 
diamonds) or normal rabbit sera (NRS, triangles). A third set of wells was coated with an 
irrelevant MAPS antigen (negative control) containing a peptide from MtrC. These wells 
were incubated with two-fold serial dilutions of Stase-MAPS-APl antiserum, as 
described above (Anti-MAPS (MtrC Ag), squares). 
3-5. Western Blot Detection of Stase 
The subcellular fractions of both strains F62 and STOl were run on a 10% SDS-
PAGE gel with 12 ± l^ig of protein/lane (as determined by BCA protein assay). The gel 
was blotted and probed with Stase-MAPS-APl antiserum (Figure 8). An 
immunoreactive band corresponding to Stase (43 kDa) was detected in the F62 whole cell 
lane (positive control) and in the F62 outer membrane lane demonstrating that Stase is an 
outer membrane protein. No Stase was detected in any other subcellular fraction of strain 
F62 or in any of the subcellular fractions of strain STOl (negative control). The Stase-
MAPS-APl antiserum contained many cross-reactive antibodies resulting in a variety of 
bands at other molecular weights. 
A Western blot of F62 and STOl supernatant, 0.09mg/lane, probed with rabbit 
Stase antiserum (see Materials and Methods) detected no Stase (data not shown). When 
the supematants were concentrated over eight times, 0.75mg/lane, Western blotted and 
probed with Stase/MBP antiserum, there was still no evidence of Stase (Figure 9). 
3-6. Cloning of Stase into pMAL Fusion System 
The PGR product containing the gene encoding Stase with the engineered Xba I 
and ZicoR I endonuclease cleavage sites (see Materials and Methods) was cloned into the 
pMAL-c2 vector and transformed into DH5a cells. The colonies of transformed cells 
were white and grew on LB-Amp-X-gal-IPTG plates. When plasmid preparations were 
made from cultures of these colonies, double digested -with Xba I and EcdR. I, and run on 
an agarose gel, two bands corresponding to the 1.1 kb Stase insert and the 6.6 kb plasmid 
vector were apparent. 
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Coomassie Stain and Western Blot of the Subcellular Fractions of 
N. gonorrhoeae Strains F62 and STOl Probed with Stase-MAPS-
APl Antiserum 
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Figure 8. Detection of Stase in strains F62 and F62 STOl of N. gonorrhoeae was 
performed by Western blot of a 10% SDS-PAGE gel probed with Stase-MAPS-AP 1 
antiserum. Subcellular fractions were run with \2±\\xg of protein per lane. The left 
panel shows a Coomassie Brilliant Blue (CBB) stain of a 10% SDS-PAGE gel 
corresponding to the accompanying Western blot. Bands corresponding to Stase were 
detected in the lanes containing F62 whole cell lysate (F62 WC) and F62 outer membrane 
(F62 OM). WC- whole cell lysate, OM- outer membrane. Peri.- periplasm, IM- inner 
membrane, Cyto.- cytoplasm, MW- molecular weight markers, expressed in kilodaltons 
(kDa). 
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Coomassie Stain and Western Blot of Culture Supernatant of 
gonorrhoeae Strains F62 and F62 STOl Probed with Stase/MBP 
Antiserum 
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Figure 9. A 10% SDS-PAGE gel stained with Coomassie Brilliant Blue and a Western 
blot probed with Stase/MBP antiserum failed to detect the presence of Stase in 
concentrated supernatant fractions of either N. gonorrhoeae strain F62 or strain F62 
STOl (negative control) although the antiserum was capable of detecting Stase (F62 WC 
lane, positive control). WC- whole cell lysate. Sup. supernatant, MW- molecular weight 
markers, expressed in kilodaltons (kDa). 
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Sequence data confirmed the correct orientation and location of the engineered Stase 
insert. The pMAL-Stase plasmid encodes a MBP/Stase fixsion protein (Figure 10). The 
ochre stop codon of the Stase gene prevents the expression of the lacZa gene product, P-
galactosidase a as demonstrated by the white color of pMAL-Stase transformed colonies. 
3-7. Expression of MBP/Stase Fusion Protein 
Cells transformed with the plasmid described above were grown, induced and 
treated as described in Materials and Methods. Fusion protein eluted from the amylose 
resin was visualized on a coomassie brilliant blue stained 10% SDS-PAGE gel (Figure 
11), which showed a band at slightly less than 93 kDa. The expected molecular weight of 
the fusion was approximately 85 kDa. The identity of the fusion protein was further 
confirmed by Western blot using Stase antiserum provided by Dr. Rick Rest (AUHS) (see 
Materials and Methods), which reacted with the fusion protein, but not with a MB? 
control (Figure 12). 
3-8. Generation of Stase/MBP Antisera and Detection of Stase 
The MBP/Stase fusion protein was used to immunize New Zealand white rabbit 
(see Materials and Methods). When the antisera generated was used to probe a Western 
blot containing the subcellular fi'actions of both strains F62 and STOl, Stase was only 
detected in the lanes containing F62 whole cell lysate and F62 outer membrane (Figure 
13). This confirmed the hypothesis that the cellular location of Stase was the outer 
membrane. Most of the cross-reactive antibodies were preabsorbed by E. coli DH5a cell 
lysate (see Materials and Methods). 
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Figure 10. The pMAL-Stase piasmid construct contains an insert (bold) of the Stase 
gene with engineered restriction endonuclease sites {EcoR I and Xba I). Ptac is an 
inducible promoter under the repressor control of the lad gene product. Derepression 
occurred when IPTG was added to the system. The lacZa gene product was not 
expressed because of the stop codon found at the end of the Stase gene. The malE gene 
encodes MBP (without a signal sequence) which was fused to Stase and expressed in the 
cytoplasm. Ampicillin resistance provided a selectable marker for the piasmid. 
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Figure 11. Purified fusion protein MBP/Stase was detected by Coomassie Brilliant Blue 
stain of a 10% SDS-PAGE gel. The single band in the Fusion lane correspond to the 
expected Mr of the MBP/Stase fusion protein (85 kDa). Induced E. coli DH5a cells 
containing the pMAL-Stase plasmid show a corresponding band that is essentially absent 
from the whole cell lysate of DH5a cells containing the pMAL-c plasmid without the 
Stase gene insert. MW- molecular weight markers, expressed in kilodaltons (kDa). 
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Figure 12. A Western blot probed with Stase antiserum (a gift from Dr. Rick Rest, see 
Materials and Methods) showed the presence of the fusion protein in E. coli DH5a cells 
harboring the pMAL-Stase plasmid, as well as confirming the identity of the purified 
plasmid protein (asterisks indicate fusion protein). Stase antiserum did not react with a 
band of the predicted fusion Mr (85 kDa) in DH5a cells or DH5a cells containing the 
pMAL-c plasmid without the Stase gene insert. Neither did it react with MBP alone. A 
band corresponding the Stase (43 kDa) was detected in the N. gonorrhoeae F62 outer 
membrane lane (positive control). MW- molecular weight markers, expressed in 
kilodaltons (kDa), WC- whole cell lysate, OM- outer membrane. 
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Coomassie Stain and Western Blot of the Subcellular Fractions of 
N. gonorrhoeae Strains F62 and F62 STOl Probed with 
Stase/MBP Antiserum 
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Figure 13. Detection of Stase was performed by Western blot of a 10% SDS-PAGE gel 
probed with Stase/MBP antiserum. Subcellular fractions were run with 12 ±l|j.g of 
protein per lane. The left panel shows a Coomassie Brilliant Blue (CBB) stain of the 
SDS-PAGE gel corresponding to the accompanying Western blot. Only the lanes with 
F62 whole cell lysate (F62 WC) or F62 outer membrane (F62 OM) contained Stase. 
WC- whole cell lysate, OM- outer membrane. Peri.- periplasm, IM- inner membrane, 
Cyto - cytoplasm, MW- molecular weight markers, expressed in kilodaltons (kDa). 
4. DISCUSSION 
Gonococcal diseases are a significant problem among populations in the United 
States and Europe that exhibit high risk behaviors. These populations include 
adolescents, certain minority groups and people living in inner cities. Many developing 
countries also have high rates of gonococcal disease, and gonococci continue to develop 
antibiotic resistance (Mabey, 1996; Piot and Islam, 1994). Penicillin and tetracycline-
resistant gonococci make up more than 50% of gonococcal isolates in many countries in 
Africa and Asia (Mabey, 1996). Furthermore, evidence indicates that transmission of the 
HIV virus is increased among partners with gonococcal infection or other bacterial 
sexually transmitted diseases (Sparling, et al., 1994; Mabey, 1996). To date, there is no 
effective vaccine available. 
This study focused on the identification of the subcellular location of the 
gonococcal a-2,3-sialyltransferase (Stase), an enzyme that appears to enhance the 
persistence of gonococcal infection by the transfer of sialic acid from the host donor 
molecule, CMP-NANA, to the bacterial surface LOS (Mandrell, et al, 1993). The 
presence of sialic acid on the Gaipi-4NAcGlu moiety of a 4.5 kDa LOS molecule 
expressed by many strains of N. gonorrhoeae enhances the serum resistance of the 
bacteria (Smith, et al, 1995). Serum resistance is enhanced by decreasing the 
effectiveness of IgM mediated killing (Smith, et al, 1995), by reducing the binding of 
complement protein C3, by enhancing the cleavage of C3b to an inactive form, and by 
increasing the binding of Factor H which binds C3b preventing the formation of the C3 
convertase of the alternative complement pathway (Smith, et al, 1995; Kuby, 1997). 
Sialylation has also been shown to delay complement-mediated opsonophagocytosis 
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(Kim, et al, 1992) and to increase the resistance of gonococci to phagocytic killing by 
PMNs (Gill, et ai, 1996). 
Determining the cellular location of Stase is a relevant step toward the goal of 
understanding and defeating the mechanisms used by gonococci to persist in the host. If 
Stase is located on the bacterial surface (i.e. in the outer membrane), further studies of the 
action of anti-Stase antibodies are warranted. The hypothesis that Stase was located 
primarily in the outer membrane of N. gonorrhoeae was tested by enzymatic assays and 
Western blots of subcellular fractions of the bacterium. The first step in locating Stase 
was the isolation of the various subcellular fractions, including the outer membrane, 
periplasm, inner membrane and cytoplasm. It seemed unlikely that gonococci would 
secrete Stase into the surroundings as this would be wasteful and inefficient, but the 
supernatant was also collected to test this possibility. 
Separations of the inner and outer membranes were accomplished by a sucrose 
density gradient centrifugation procedure previously shown to give clearly identifiable 
inner and outer membrane fractions (Dr. Ralph Judd, personal communication). The 
membrane separations of the wild type gonococcal strain F62 and the Stase-deficient 
mutant strain F62 STOl used as a negative control, showed protein peaks at virtually 
identical densities (Figures lA and IB) further demonstrating the reliability of this 
membrane isolation procedure. 
The vast majority of Stase enzymatic activity was found in the outer membrane of 
strain F62, with the specific activity of the outer membrane being over 30 times higher 
than the specific activity in the inner membrane fraction. Outer membrane proteins must 
pass through the inner membrane on their way to insertion in the outer membrane, thus 
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the shght amount of activity found in the inner membrane may be due to Stase in transit. 
It is also possible that a small overlap in the membrane peaks (Figure 1 A), may account 
for the presence of Stase activity in the inner membrane fraction. No Stase activity was 
detected in any other fraction tested. 
The hypothesis that Stase was located in the outer membrane was further 
confirmed by Western blot using rabbit antiserum generated to an octomeric MAPS 
peptide bearing the Stase amino acid sequence: ^^ENRNEKYDYYF^^. This sequence 
was shown by MacVector software using the Kyte-Doolittle algorithm to have the highest 
hydrophilicity In addition, it had a high predicted surface probability, flexibility, and a 
high antigenic index that takes into account the previous information as well as the 
predicted secondary structure (Jameson and Wolf, 1988). The MAPS peptide was shown 
by ELISA to be adequately immunogenic (Figure 7). When Stase-MAPS-APl antiserum 
was used to probe a Western blot containing the various subcellular fractions, a band of 
the appropriate (43 kDa) molecular mass was seen in the whole cell lysate of strain F62 
and in the F62 outer membrane fraction, but not in any other subcellular fraction, 
confirming that Stase was located in the outer membrane. K gonorrhoeae is a typical 
gram-negative bacteria, so the presence of cross-reactive antibodies in the Stase-MAPS-
APl antiserum, resulting in the detection of other bands of various molecular weights, 
was not surprising. 
The absence of a 43 kDa protein band corresponding to Stase in lanes containing 
the mutant strain F62 STOl whole cell lysate and outer membrane, confirmed the identity 
of the Stase protein band in the wild type F62 whole cell and outer membrane lanes. 
Evidence that the Stase gene in strain STOl was disrupted by a kanamycin resistance 
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cassette, and therefore not expressed, came from PCR that used STOl genomic DNA as 
the template and primers complementary to the 5' and 3' ends of the gene encoding 
Stase. The resulting PCR product contained a major band roughly 1000 base pairs higher 
than the PCR product obtained when wild type F62 DNA was used as the template (data 
not shown). This confirmed the insertion of the kanamycin resistance cassette into the 
gene. 
One of the advantages of MAPS immunogens is that they generate antibody to a 
very small number of epitopes. It is a rapid and easy way to generate specific antibodies 
(Yen, 1995). However, this specificity makes them more difficult to use in Western blot 
detection when the protein of interest is present in small quantities because each molecule 
of protein may have just a few binding sites. If antibody were generated to a mixture of 
immunogenic MAPS antigens, this problem might be overcome. 
The antibody-generating response against a whole protein tends to be stronger 
than the response to a MAPS immunogen, perhaps because of the abundance of B and T 
cell epitopes available. Purified Stase is very difficult to obtain, presumably, because it is 
a minor outer membrane protein. Generating the recombinant protein in E. coli was thus 
a useful method for obtaining enough protein for antisera production. To this end the 
gene encoding Stase was cloned into the pMAL-c2 plasmid and used to transform E. coli. 
Cells containing the plasmid were induced with IPTG, and the resulting fusion protein, 
MBP/Stase, was affinity-purified on amylose resin. Addition of maltose allowed the 
removal of the fusion protein from the resin. The purified fusion protein was used to 
generate Stase/MBP antiserum, which was used to probe a Western blot identical to the 
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one described above, with similar results, further confirming that Stase was located in the 
outer membrane. 
The only data at variance with the hypothesis that Stase was an outer membrane 
protein was the presence of an N-terminal signal peptide that was predicted by computer 
algorithms to be uncleavable and to target Stase to the inner membrane (Gilbert, et al, 
1996). The protein sequence used for the prediction was based on the Stase gene from N. 
meningitidis, which differs from the gonococcal strain F62 protein by 16 or 17 amino 
acids depending on the N. meningitidis strain used for comparison (Gilbert, et al, 1996). 
However, only one of the amino acid differences occurs in the region predicted to contain 
the signal peptide. The algorithms used to predict protein localization have an overall 
success rate of 83% (Nakai and Kanehisa, 1991). The data in this study clearly showed 
the computer prediction to be inaccurate by demonstrating that Stase was an outer 
membrane protein. 
Sialylation is known to abrogate the bactericidal effects of normal rabbit sera, 
rabbit anti-PorA and anti-PorB sera, rabbit anti-gonococcal whole cell sera, and normal 
human antisera that contains anti-LOS antibodies (Wetzler, et al, 1992). It has been 
suggested that the structural and antigenic similarity of sialylatable LOS to 
paragloboside, a precursor for the major blood group antigens (ABH), may mask the 
bacterium decreasing the immune reaction of the host (Mandrell and Apicella, 1993). 
Sialylation of these LOS molecules increases their similarity to sialylated glycoproteins 
and certain glycosphingolipids (Smith, et al., 1995; Mandrell, et al, 1990) and may serve 
to enhance this effect. Sialylation also interferes with complement-mediated serum 
killing and phagocytosis as described above, leading to a serum-resistant phenotype. 
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The serum resistance caused by sialylation can be lost on subculture and is termed 
unstable serum resistance. It is most common in cases of uncomplicated gonococcal 
infection and in cases such as acute salpingitis where a significant inflammatory response 
is induced (Rice, 1989). Gonococci with a stable serum resistant phenotype have been 
found in most cases of DGI, which occur in 1 to 3% of gonococcal infections (Rice, 
1989; Schoolnik, et ai, 1976). Stable serum-resistant gonococci did not become serum-
sensitive when treated with neuraminidase, an enzyme that cleaves sialic acid from LOS 
molecules, indicating that this type of serum resistance was not caused by sialylation 
(Parsons, et al, 1992). A vaccine that prevented unstable serum resistance by decreasing 
the ability of the gonococci to sialylate themselves would be useful in the majority of 
cases and could lead to a decrease in the prevalence of gonococcal infection. 
Since it was shown by two methods, enzymatic assay and Western blotting, that 
Stase was an outer membrane protein, experiments determining whether Stase antiserum 
inhibits sialylation of the bacteria are warranted. If this can be shown to occur in vitro. 
Stase may be a potential vaccine candidate because it may serve to decrease the 
pathogenicity of the bacteria and allow the immune system to destroy them. Due to the 
similarity of gonococcal Stase to the a-2,3-sialyltransferase of N. meningitidis, and the 
conserved nature of Stase among the meningococcal strains examined (Gilbert, et al, 
1996), it is likely that Stase has a fairly conserved sequence among gonococcal strains. It 
would be of interest to know if Stase antiserum is bactericidal in serum killing assays. If 
so. Stase alone may be an excellent vaccine target. If antibodies against Stase are not 
sufficient to cause serum killing, but are able to block sialylation of the gonococcal LOS, 
it would be worth considering Stase vaccination in combination with other gonococcal 
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outer membrane protein epitopes. Since the most immunodominant epitopes on the 
gonococcal surface tend to be quite variable, antibodies against a conserved 
immxmorecessive epitope might exhibit increased bactericidal activity if the bacteria are 
unable to sialylate their LOS. The antisera generated in this project will be useful in 
assessing the potential of Stase as a vaccine candidate. 
In summary, the hypothesis that Stase is located in the outer membrane of N. 
gonorrhoeae was supported by enzymatic assay data and Western blot detection. Stase-
MAPS-APl antiserum was made against a MAPS immunogen that consisted of eight 
copies of an eleven amino acid peptide from Stase, selected based on its predicted 
hydrophilicity, surface probability, flexibility and antigenic index. Stase/MBP antiserum 
was generated against a fusion protein, MBP/Stase, expressed by E. coli harboring the 
pMAL-Stase plasmid vector. Both antisera were used in Western blot detection of Stase 
and will be helpful in evaluating the potential of Stase as a vaccine candidate either by 
itself or in conjunction with epitope(s) from other gonococcal outer membrane proteins. 
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